SB4622, the Protecting Americans from Treatment-related Credit Harm Act, would amend the Fair Credit Reporting Act to bar medical debt from appearing on consumer reports. It defines medical debt broadly as debt arising from medical services, products, or devices, and rewrites the FCRA’s adverse-information provisions so that medical debt, including debt sent to collections or charged off, cannot be included in a consumer report used for credit-related purposes.
The bill also directs the Consumer Financial Protection Bureau to revise its regulations within one year so creditors are prohibited from obtaining or using medical-debt information when deciding whether to extend credit. In practical terms, the measure would change both credit reporting practices and underwriting rules, limiting the role of medical bills in consumer credit decisions and affecting consumer reporting agencies, creditors, and borrowers with unpaid medical expenses.
If enacted, the bill would amend key provisions of the Fair Credit Reporting Act, especially sections governing adverse information on consumer reports and the use of medical information in credit decisions. It would remove medical debt from the categories of information that may be reported as negative credit history and require conforming regulatory changes at the CFPB to prevent creditors from using medical-debt data in underwriting. The main affected parties would be consumers with medical debt, credit bureaus, lenders, and the CFPB, with the likely effect of reducing credit-score harm tied to health-related bills.
The available context suggests a generally favorable, consumer-protection-oriented purpose, with the bill framed as shielding Americans from credit harm caused by medical treatment costs. No committee transcript or vote record is provided, so there is no recorded opposition or formal debate to gauge broader sentiment. Based on the text alone, the bill appears designed to address a widely recognized fairness concern in credit reporting.
The central policy issue is whether medical debt should be treated differently from other consumer debt in credit reporting and lending decisions. Supporters would likely argue that medical debt is often unexpected, not a reliable indicator of creditworthiness, and can unfairly penalize people for seeking care. Potential critics may argue that removing medical debt from credit files could reduce information available to lenders and complicate risk assessment, but no specific objections are documented in the provided materials.